Chemomab Therapeutics (CMMB) Tax Provisions (2022 - 2023)

Chemomab Therapeutics (CMMB) posted Tax Provisions of -$55000.0 for Q3 2023, down 261.76% on a QoQ basis from $34000.0 in Q2 2023.

Chemomab Therapeutics (CMMB) Tax Provisions (2022 - 2023) Analysis & Trends

Chemomab Therapeutics' Tax Provisions history runs 2 years deep, the most recent figure standing at -$55000.0 for Q3 2023.

Quarterly Tax Provisions changed N/A year-over-year to -$55000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $10000.0 (up 101.84% YoY) and the FY2022 annual result came in at -$534000.0, changed N/A from the prior year.
Tax Provisions was -$55000.0 for Q3 2023 at Chemomab Therapeutics, down from $34000.0 in the prior quarter.
Across five years, Tax Provisions topped out at $34000.0 in Q2 2023 and bottomed at -$544000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	125,146.46
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-859,000.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	31.86 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	221.50 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	104.00 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-60.00 Mn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Chemomab Therapeutics	704.11 Mn	693.75 Mn	-	-

Download Data